Genetic Technologies Limited (GNTLF)
USD 1.0
(0.0%)
USD 1.0
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 4.35 Million AUD | 17.93% |
| 2023 | 3.69 Million AUD | -15.49% |
| 2022 | 4.37 Million AUD | 203.8% |
| 2021 | 1.43 Million AUD | -45.04% |
| 2020 | 2.61 Million AUD | 75.23% |
| 2019 | 1.49 Million AUD | 2.73% |
| 2018 | 1.45 Million AUD | -4.91% |
| 2017 | 1.52 Million AUD | 8.73% |
| 2016 | 1.4 Million AUD | -20.11% |
| 2015 | 1.76 Million AUD | -64.08% |
| 2014 | 4.9 Million AUD | 91.38% |
| 2013 | 2.56 Million AUD | 25.61% |
| 2012 | 2.03 Million AUD | -3.28% |
| 2011 | 2.1 Million AUD | -17.7% |
| 2010 | 2.56 Million AUD | -46.51% |
| 2009 | 4.78 Million AUD | 44.42% |
| 2008 | 3.31 Million AUD | -18.12% |
| 2007 | 4.05 Million AUD | -3.01% |
| 2006 | 4.17 Million AUD | -35.85% |
| 2005 | 6.5 Million AUD | 22.35% |
| 2004 | 5.32 Million AUD | 79.25% |
| 2003 | 2.96 Million AUD | 59.17% |
| 2002 | 1.86 Million AUD | 15.24% |
| 2001 | 1.61 Million AUD | 27.42% |
| 2000 | 1.26 Million AUD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 3.65 Million AUD | -1.05% |
| 2024 Q4 | 4.35 Million AUD | 0.0% |
| 2024 FY | 4.35 Million AUD | 17.93% |
| 2024 Q2 | 3.65 Million AUD | 0.0% |
| 2023 FY | 3.69 Million AUD | -15.49% |
| 2023 Q4 | 3.69 Million AUD | 0.0% |
| 2023 Q3 | 3.69 Million AUD | -20.84% |
| 2023 Q1 | 4.66 Million AUD | 6.76% |
| 2023 Q2 | 4.66 Million AUD | 0.0% |
| 2022 FY | 4.37 Million AUD | 203.8% |
| 2022 Q3 | 4.37 Million AUD | 41.39% |
| 2022 Q4 | 4.37 Million AUD | 0.0% |
| 2022 Q2 | 3.09 Million AUD | 0.0% |
| 2022 Q1 | 3.09 Million AUD | 114.87% |
| 2021 Q4 | 1.43 Million AUD | 0.0% |
| 2021 Q2 | 1.36 Million AUD | 0.0% |
| 2021 Q1 | 1.36 Million AUD | -47.94% |
| 2021 FY | 1.43 Million AUD | -45.04% |
| 2021 Q3 | 1.43 Million AUD | 5.58% |
| 2020 Q4 | 2.61 Million AUD | 59.57% |
| 2020 Q1 | 1.48 Million AUD | -0.84% |
| 2020 Q2 | 1.48 Million AUD | 0.0% |
| 2020 Q3 | 1.64 Million AUD | 10.74% |
| 2020 FY | 2.61 Million AUD | 75.23% |
| 2019 FY | 1.49 Million AUD | 2.73% |
| 2019 Q2 | 1.09 Million AUD | 9.14% |
| 2019 Q1 | 1 Million AUD | -30.87% |
| 2019 Q3 | 1.49 Million AUD | 36.09% |
| 2019 Q4 | 1.49 Million AUD | 0.05% |
| 2018 Q1 | 1.18 Million AUD | -22.67% |
| 2018 Q4 | 1.45 Million AUD | 0.23% |
| 2018 Q3 | 1.45 Million AUD | 19.58% |
| 2018 FY | 1.45 Million AUD | -4.91% |
| 2018 Q2 | 1.21 Million AUD | 2.59% |
| 2017 Q4 | 1.52 Million AUD | 4.36% |
| 2017 Q3 | 1.46 Million AUD | -17.08% |
| 2017 Q2 | 1.76 Million AUD | 3.94% |
| 2017 Q1 | 1.7 Million AUD | 20.87% |
| 2017 FY | 1.52 Million AUD | 8.73% |
| 2016 Q4 | 1.4 Million AUD | 5.58% |
| 2016 Q3 | 1.33 Million AUD | 7.9% |
| 2016 Q2 | 1.23 Million AUD | 7.03% |
| 2016 Q1 | 1.15 Million AUD | -34.47% |
| 2016 FY | 1.4 Million AUD | -20.11% |
| 2015 Q1 | 3.14 Million AUD | -35.76% |
| 2015 Q3 | 1.73 Million AUD | -44.9% |
| 2015 Q2 | 3.14 Million AUD | 0.0% |
| 2015 FY | 1.76 Million AUD | -64.08% |
| 2015 Q4 | 1.76 Million AUD | 1.46% |
| 2014 Q2 | 7.91 Million AUD | 0.0% |
| 2014 Q1 | 7.91 Million AUD | 209.2% |
| 2014 Q4 | 4.9 Million AUD | 0.0% |
| 2014 Q3 | 4.9 Million AUD | -38.11% |
| 2014 FY | 4.9 Million AUD | 91.38% |
| 2013 Q3 | 2.46 Million AUD | 29.38% |
| 2013 FY | 2.56 Million AUD | 25.61% |
| 2013 Q4 | 2.56 Million AUD | 3.9% |
| 2013 Q2 | 1.9 Million AUD | 0.0% |
| 2012 Q2 | 1.6 Million AUD | 0.0% |
| 2012 FY | 2.03 Million AUD | -3.28% |
| 2012 Q4 | 2.03 Million AUD | 0.0% |
| 2011 FY | 2.1 Million AUD | -17.7% |
| 2011 Q4 | 2.1 Million AUD | 0.0% |
| 2011 Q2 | 2.39 Million AUD | 0.0% |
| 2010 Q2 | 2.82 Million AUD | 0.0% |
| 2010 FY | 2.56 Million AUD | -46.51% |
| 2010 Q4 | 2.56 Million AUD | 0.0% |
| 2009 FY | 4.78 Million AUD | 44.42% |
| 2009 Q2 | 3.6 Million AUD | 0.0% |
| 2009 Q4 | 3.86 Million AUD | 0.0% |
| 2008 FY | 3.31 Million AUD | -18.12% |
| 2008 Q2 | 2.71 Million AUD | 0.0% |
| 2008 Q4 | 3.31 Million AUD | 0.0% |
| 2007 FY | 4.05 Million AUD | -3.01% |
| 2007 Q4 | 4.05 Million AUD | 0.0% |
| 2007 Q2 | 3.88 Million AUD | 0.0% |
| 2006 FY | 4.17 Million AUD | -35.85% |
| 2006 Q4 | 4.17 Million AUD | 0.0% |
| 2006 Q2 | 3.71 Million AUD | 0.0% |
| 2005 Q2 | 4.7 Million AUD | 0.0% |
| 2005 Q4 | 6.5 Million AUD | 0.0% |
| 2005 FY | 6.5 Million AUD | 22.35% |
| 2004 FY | 5.32 Million AUD | 79.25% |
| 2003 FY | 2.96 Million AUD | 59.17% |
| 2002 FY | 1.86 Million AUD | 15.24% |
| 2001 FY | 1.61 Million AUD | 27.42% |
| 2000 FY | 1.26 Million AUD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| American Bio Medica Corporation | 3.6 Million USD | -20.735% |
| Arrayit Corporation | 7.49 Million USD | 41.892% |
| Atlantic International Corp. | 3.82 Million USD | -13.778% |
| Biocept, Inc. | 22.01 Million USD | 80.211% |
| Bioqual, Inc. | 18.93 Million USD | 76.998% |
| CardioGenics Holdings Inc | 1.79 Million USD | -142.69% |
| DermTech, Inc. | 64.75 Million USD | 93.273% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 734.97 Million USD | 99.407% |
| HTG Molecular Diagnostics, Inc. | 12.38 Million USD | 64.83% |
| iMD Companies, Inc. | 1.67 Million USD | -160.188% |
| IDenta Corp. | 1.01 Million USD | -329.953% |
| Interpace Biosciences, Inc. | 28.15 Million USD | 84.529% |
| Integrative Health Technologies, Inc. | 297.94 Thousand USD | -1362.041% |
| InVitro International | 78.99 Thousand USD | -5414.756% |
| Lumos Diagnostics Holdings Limited | 19.72 Million USD | 77.92% |
| Many Bright Ideas Technologies Inc. | 129.29 Thousand USD | -3269.07% |
| Medical Imaging Corp. | 9.51 Million USD | 54.229% |
| NovelStem International Corp. | 4.2 Million USD | -3.567% |
| Optigenex Inc. | 9.57 Million USD | 54.485% |
| PharmChem, Inc. | 558.64 Thousand USD | -679.76% |
| Proteome Sciences plc | 18.48 Million USD | 76.44% |
| Response Genetics, Inc | 15.86 Million USD | 72.546% |
| Rennova Health, Inc. | 49.66 Million USD | 91.229% |
| RushNet, Inc. | 6.23 Million USD | 30.179% |
| ScreenPro Security Inc. | 1.6 Million USD | -172.157% |
| Stella Diagnostics Inc. | 18 Million USD | 75.807% |
| StageZero Life Sciences Ltd. | 8.2 Million USD | 46.903% |
| Todos Medical Ltd. | 50.15 Million USD | 91.315% |